APA

Borg C., Mantion G., Boudghène F., Mornex F., Ghiringhelli F., Adenis A., Azria D., Balosso J., Ben Abdelghani M., Bachet J. B., Vendrely V., François Y., Conroy T., Rio E., Roullet B., Spaëth D., Quero L., Lakkis Z., Coudert M., Ionescu-Goga M., Tanang A. & André T. (20200529). Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. : Clinical colorectal cancer.

Chicago

Borg Christophe, Mantion Georges, Boudghène Frank, Mornex Françoise, Ghiringhelli François, Adenis Antoine, Azria David, Balosso Jacques, Ben Abdelghani Meher, Bachet Jean Baptiste, Vendrely Véronique, François Yves, Conroy Thierry, Rio Emmanuel, Roullet Bernard, Spaëth Dominique, Quero Laurent, Lakkis Zaher, Coudert Mathieu, Ionescu-Goga Miruna, Tanang Alexandre and André Thierry. 20200529. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. : Clinical colorectal cancer.

Harvard

Borg C., Mantion G., Boudghène F., Mornex F., Ghiringhelli F., Adenis A., Azria D., Balosso J., Ben Abdelghani M., Bachet J. B., Vendrely V., François Y., Conroy T., Rio E., Roullet B., Spaëth D., Quero L., Lakkis Z., Coudert M., Ionescu-Goga M., Tanang A. and André T. (20200529). Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. : Clinical colorectal cancer.

MLA

Borg Christophe, Mantion Georges, Boudghène Frank, Mornex Françoise, Ghiringhelli François, Adenis Antoine, Azria David, Balosso Jacques, Ben Abdelghani Meher, Bachet Jean Baptiste, Vendrely Véronique, François Yves, Conroy Thierry, Rio Emmanuel, Roullet Bernard, Spaëth Dominique, Quero Laurent, Lakkis Zaher, Coudert Mathieu, Ionescu-Goga Miruna, Tanang Alexandre and André Thierry. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. : Clinical colorectal cancer. 20200529.